A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Lymphoma Clinical Trial

Official title:

PH-139: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04827810
• Other study ID #: 21-1045
• Secondary ID: 1R01CA225913-01A
• Status: Suspended
• Phase: Phase 1
• Start date: November 5, 2021
• Est. completion date: December 30, 2026

Study information

• Verified date: May 2024
• Source: Fox Chase Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib. In the dose-finding portion of this study, gamitrinib formulated in Lipoid S100®-based formulation will be administered as a 1-hour IV infusion once weekly for four weeks as 28-day treatment cycles. Up to 36 patients will be enrolled in the dose-escalation component of the study based on anticipated cohorts. The starting dose will be 10 mg, corresponding to allometric scaling) from the most sensitive species (rats) in the 29-day GLP toxicology and toxicokinetic studies with 14-day recovery period of gamitrinib. Dose-escalation will follow a 3+3 design. Six patients will be enrolled in the dose-expansion component of the study at MTD for the purpose of exploring pharmacodynamic effects via tumor pre and on-therapy biopsies.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 42
• Est. completion date: December 30, 2026
• Est. primary completion date: June 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of advanced cancer refractory to standard of care therapy, or for whom no standard of care therapy is available. Any numbers of prior therapies are allowed.
• Dose escalation phase: Solid tumors and lymphoma may have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST v. 1.1) or as per RECIL 2017 criteria
• Dose expansion phase:

i. All patients must have at least one site of measurable disease as defined by RECIST v. 1.1. or RECIL 2017, for solid tumors and lymphoma, respectively ii. Patients in the expansion cohort must have at least one non-target lesion deemed safe to biopsy, in the opinion of the investigator, and be willing to undergo mandatory core biopsies. This includes pre-treatment and an on-treatment biopsy. Biopsies at the time of progression are highly desired, but optional. iii. The lesion(s) which will be used for response assessment may not be biopsied iv. Target lesions that have been previously irradiated will not be considered measurable unless increase in size is observed following completion of radiation therapy

• All previous therapies of cancer, including radiotherapy major surgery and investigational therapies must be discontinued for =14 days (= 28 days for mitomycin C or nitrosoureas) before Cycle 1 Day 1 (C1D1), and all acute effects of any prior therapy must have resolved to baseline severity or Grade = 1 Common Terminology Criteria for Adverse Events (CTCAE v5), except alopecia or parameters defined in this eligibility list.
• Age > 18 years.
• ECOG performance status 0- 2
• Patients must have normal organ and marrow function as defined below
• Absolute neutrophil count =1,500/mm3 without growth factor use = 7 days prior to C1D1 Platelets =85,000/mm3 without platelet transfusion = 7 days prior to C1D1 Hemoglobin >8.5 mg/dL without red blood cell transfusion = 7 days prior to C1D1 Total serum bilirubin <1.5 X upper limit of normal (ULN) (except for patients with documented Gilbert's syndrome) AST (SGOT)/ALT (SGPT) =2 X ULN; = 5 X ULN if liver dysfunction is felt to be secondary to tumor burden Serum creatinine = 1.5 X ULN (OR creatinine clearance = 60 mL/min/1.73 m2) Serum or urine pregnancy test (WOCBP only) negative =7 days of C1D1
• Ability to understand and willingness to sign a written informed consent, HIPAA consent document and comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.
• Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.

Exclusion Criteria:

• Patients with symptomatic brain metastases are excluded. Patients with asymptomatic and treated CNS metastases may participate in this trial. The patient must have completed any prior treatment for CNS metastases > 28 days prior to study entry, including radiotherapy or surgery. Concurrent use of steroids for the treatment of brain metastasis are not permitted.
• Current treatment on another (therapeutic) clinical trial
• Hypertension not adequately controlled with medications (>150/100 mm Hg despite optimal medical therapy)
• Active bacterial fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), requiring treatment with IV antibiotic, IV anti-fungal, or anti-viral (Testing is not required for eligibility).
• Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (testing is not required for eligibility).
• Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study
• Pregnant or breast feeding. Refer to section 4.4 for further detail.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Lymphoma

Intervention

Drug:
• Gamitrinib
This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.

Locations

Country	Name	City	State
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Fox Chase Cancer Center	National Cancer Institute (NCI), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the MTD and/or RP2D of gamitrinib when administered once weekly.	First cycle dose-limiting toxicities. The maximally tolerated dose (MTD) is defined as the dose level below which the absolute observed DLT rate is > 25%. The MTD is equivalent to the anticipated recommended phase 2 dose (RP2D).	7 years
Secondary	Evaluate the overall safety profile of intravenously administered single-agent gamitrinib	Overall, safety profile of gamitrinib as characterized by type, frequency, severity, timing and relationship to study therapy of adverse events and laboratory abnormalities according to NCI CTCAE v5.0.	7 years
Secondary	To evaluate the peak concentration (Cmax) of gamitrinib	Blood sample will be collected for determination of gamitrinib plasma concentrations. The PK parameter to be evaluated includes peak concentration (Cmax).	7 years
Secondary	To evaluate the area under the concentration time curve (AUC0-t) of gamitrinib	Blood sample will be collected for determination of gamitrinib plasma concentrations. PK parameter to be evaluated includes area under the concentration time curve (AUC0-t).	7 years
Secondary	To evaluate the clearance (CL) of gamitrinib	Blood sample will be collected for determination of gamitrinib plasma concentrations. PK parameter to be evaluated includes clearance (CL).	7 years
Secondary	To evaluate the time to maximum concentration (Tmax) of gamitrinib	Blood sample will be collected for determination of gamitrinib plasma concentrations. PK parameter to be evaluated includes time to maximum concentration (Tmax).	7 years
Secondary	To evaluate the coefficient of variation (CV) of gamitrinib	Blood sample will be collected for determination of gamitrinib plasma concentrations. A coefficient of variation (CV) will be assessed at each dose level.	7 years
Secondary	Assess the pharmacodynamic effects of gamitrinib	Assessment of gamitrinib effects on pharmacodynamic markers. The processed samples will be profiled for changes in the expression of 301 metabolites by Ultrahigh Performance Liquid Chromatography/Mass Spectrometry (UPLC/MS) or Gas Chromatography/Mass Spectrometry (G/MS) using the Metabolon, Inc. discovery platform	7 years
Secondary	Document any anti-tumor activity of single agent gamitrinib	Objective tumor response, as assessed using RECIST 1.1 and RECIL 2017 criteria	7 years